top of page
ACI 340B Management
Sep 20, 2024
DCSCA Compliance Raises Concerns for 340B Covered Entities and Pharmacies
The Drug Supply Chain Security Act (DCSCA), a critical piece of legislation aimed at securing the pharmaceutical supply chain, has...
ACI 340B Management
Aug 20, 2024
AbbVie Ceases Offering 340B Pricing for Orphan Drugs for Certain Covered Entities
AbbVie, a global biopharmaceutical company, recently made headlines by ceasing to offer 340B ceiling prices effective August 1, 2024, for...
ACI 340B Management
Jun 7, 2024
Enhancing Access and Care: The Role of 340B Covered Entities' Open Door Retail Pharmacies
In healthcare, accessibility, and affordability are pivotal pillars for ensuring that individuals receive the treatment and medications...
ACI 340B Management
May 16, 2024
Optimizing 340B Program Efficiency: Best Practices with TPAs and Manufacturer Blocks
The 340B Drug Pricing Program is crucial in expanding access to affordable medications for eligible healthcare organizations serving...
ACI 340B Management
Apr 17, 2024
Recent Manufacturer Restriction Updates
As of April 1st, 2024, 32 drug manufacturers have implemented various contract pharmacy restrictions for Covered Entities within the 340B...
ACI 340B Management
Mar 18, 2024
Current 340B Legislation: Transforming Healthcare Access Nationwide
340B PATIENTS ACT Federal Legislation On March 12, 2024, legislators unveiled a new federal bill that addresses systemic barriers to...
ACI 340B Management
Mar 5, 2024
The Benefits of Multiple Contract Pharmacies in the 340B Program
The 340B Drug Pricing Program has been instrumental in ensuring access to affordable medications for vulnerable populations across the...
ACI 340B Management
Feb 23, 2024
Navigating the Healthcare Maze: Unpacking the Inflation Reduction Act’s Impact on 340B Savings and Operational Resilience
The Inflation Reduction Act, a legislative initiative aimed at curbing inflation, has sparked significant discourse within various...
bottom of page